Efficacy and Safety of Tofacitinib in Chinese Patients with Active Psoriatic Arthritis: a Phase 3, Randomised, Double-Blind, Placebo-Controlled Study

Xiaomei Leng,Wei Lin,Shixue Liu,Keith Kanik,Cunshan Wang,Weiguo Wan,Zhenyu Jiang,Yi Liu,Shengyun Liu,Zhuoli Zhang,Zhiyi Zhang,Jian Xu,Wenfeng Tan,Jiankang Hu,Jingyang Li,Ju Liu,Levent M. Gunay,Oluwaseyi Dina,Cassandra Kinch,Xiaofeng Zeng
DOI: https://doi.org/10.1136/rmdopen-2022-002559
2023-01-01
RMD Open
Abstract:ObjectivesEfficacy and safety of tofacitinib, an oral Janus kinase inhibitor, were evaluated in a 6-month, double-blind, phase 3 study in Chinese patients with active (polyarthritic) psoriatic arthritis (PsA) and inadequate response to ≥1 conventional synthetic disease-modifying antirheumatic drug.MethodsPatients were randomised (2:1) to tofacitinib 5 mg twice daily (N=136) or placebo (N=68); switched to tofacitinib 5 mg twice daily after month (M)3 (blinded). Primary endpoint: American College of Rheumatology (ACR50) response at M3. Secondary endpoints (through M6) included: ACR20/50/70 response; change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI); ≥75% improvement in Psoriasis Area and Severity Index (PASI75) response, and enthesitis and dactylitis resolution. Safety was assessed throughout.ResultsThe primary endpoint was met (tofacitinib 5 mg twice daily, 38.2%; placebo, 5.9%; p<0.0001). M3 ACR20/ACR70/PASI75 responses, and enthesitis and dactylitis resolution rates, were higher and HAQ-DI reduction was greater for tofacitinib 5 mg twice daily versus placebo. Incidence of adverse events (AEs)/serious AEs (M0–3): 68.4%/0%, tofacitinib 5 mg twice daily; 75.0%/4.4%, placebo. One death was reported with placebo→tofacitinib 5 mg twice daily (due to accident). One serious infection, non-serious herpes zoster, and lung cancer case each were reported with tofacitinib 5 mg twice daily; four serious infections and one non-serious herpes zoster case were reported with placebo→tofacitinib 5 mg twice daily (M0–6). No non-melanoma skin cancer, major adverse cardiovascular or thromboembolism events were reported.ConclusionIn Chinese patients with PsA, tofacitinib efficacy was greater than placebo (primary and secondary endpoints). Tofacitinib was well tolerated; safety outcomes were consistent with the established safety profile in PsA and other indications.Trial registration numberNCT03486457.
What problem does this paper attempt to address?